| 000 | 01821 a2200565 4500 | ||
|---|---|---|---|
| 005 | 20250518041314.0 | ||
| 264 | 0 | _c20190625 | |
| 008 | 201906s 0 0 eng d | ||
| 022 | _a1532-1967 | ||
| 024 | 7 |
_a10.1016/j.ctrv.2019.04.004 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGeorge, Goldy C | |
| 245 | 0 | 0 |
_aImproving attribution of adverse events in oncology clinical trials. _h[electronic resource] |
| 260 |
_bCancer treatment reviews _cJun 2019 |
||
| 300 |
_a33-40 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAdverse Drug Reaction Reporting Systems |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 |
_aClinical Trials, Phase III as Topic _xmethods |
| 650 | 0 | 4 |
_aDrug Development _xmethods |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aRandomized Controlled Trials as Topic _xmethods |
| 700 | 1 | _aBarata, Pedro C | |
| 700 | 1 | _aCampbell, Alicyn | |
| 700 | 1 | _aChen, Alice | |
| 700 | 1 | _aCortes, Jorge E | |
| 700 | 1 | _aHyman, David M | |
| 700 | 1 | _aJones, Lee | |
| 700 | 1 | _aKaragiannis, Thomas | |
| 700 | 1 | _aKlaar, Sigrid | |
| 700 | 1 | _aLe-Rademacher, Jennifer G | |
| 700 | 1 | _aLoRusso, Patricia | |
| 700 | 1 | _aMandrekar, Sumithra J | |
| 700 | 1 | _aMerino, Diana M | |
| 700 | 1 | _aMinasian, Lori M | |
| 700 | 1 | _aMitchell, Sandra A | |
| 700 | 1 | _aMontez, Sandra | |
| 700 | 1 | _aO'Connor, Daniel J | |
| 700 | 1 | _aPettit, Syril | |
| 700 | 1 | _aSilk, Elaine | |
| 700 | 1 | _aSloan, Jeff A | |
| 700 | 1 | _aStewart, Mark | |
| 700 | 1 | _aTakimoto, Chris H | |
| 700 | 1 | _aWong, Gilbert Y | |
| 700 | 1 | _aYap, Timothy A | |
| 700 | 1 | _aCleeland, Charles S | |
| 700 | 1 | _aHong, David S | |
| 773 | 0 |
_tCancer treatment reviews _gvol. 76 _gp. 33-40 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.ctrv.2019.04.004 _zAvailable from publisher's website |
| 999 |
_c29709375 _d29709375 |
||